Lentiviral vectors for immune cells targeting

References

• Anderson, W.F., Blaese, R.M., Culver, K. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Hum. Gene Ther. 1990, 1, 331–362.
   PubMedGoogle Scholar
• Thrasher, A.J., Gaspar, H.B., Baum, C., Modlich, U., Schambach, A., Candotti, F., Otsu, M., Sorrentino, B., Scobie, L., Cameron, E., Blyth, K., Neil, J., Abina, S.H., Cavazzana-Calvo, M., Fischer, A.Gene therapy: X-SCID transgene leukaemogenicity. Nature. 2006, 443, E5–6; discussion E6.
   Web of Science ®Google Scholar
• Dass, C.R.Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy. Int. J. Pharm. 2002, 241, 1–25.
   PubMed Web of Science ®Google Scholar
• Gardlik, R., Palffy, R., Hodosy, J., Lukacs, J., Turna, J., Celec, P. Vectors and delivery systems in gene therapy. Med. Sci. Monit. 2005, 11, 110–121.
   Web of Science ®Google Scholar
• Forrest, M.L., Pack, D.W.On the kinetics of polyplex endocytic trafficking: implications for gene delivery vector design. Mol. Ther. 2002, 6, 57–66.
   PubMed Web of Science ®Google Scholar
• Edelstein, M.L., Abedi, M.R., Wixon, J.Gene therapy clinical trials worldwide to 2007–an update. J. Gene Med. 2007, 9, 833–842.
   PubMed Web of Science ®Google Scholar
• Chirmule, N., Propert, K., Magosin, S., Qian, Y., Qian, R., Wilson, J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999, 6, 1574–1583.
   PubMed Web of Science ®Google Scholar
• Kostense, S., Koudstaal, W., Sprangers, M., Weverling, G.J., Penders, G., Helmus, N., Vogels, R., Bakker, M., Berkhout, B., Havenga, M., Goudsmit, J. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004, 18, 1213–1216.
   PubMed Web of Science ®Google Scholar
• Muruve, D.A. The innate immune response to adenovirus vectors. Hum. Gene Ther. 2004, 15, 1157–1166.
   PubMed Web of Science ®Google Scholar
• Howitt, J., Anderson, C.W., Freimuth, P. Adenovirus interaction with its cellular receptor CAR. Curr. Top. Microbiol. Immunol. 2003, 272, 331–364.
   PubMed Web of Science ®Google Scholar
• Smith-Arica, J.R., Thomson, A.J., Ansell, R., Chiorini, J., Davidson, B., McWhir, J. Infection efficiency of human and mouse embryonic stem cells using adenoviral and adeno-associated viral vectors. Cloning. Stem Cells 2003, 5, 51–62.
   PubMedGoogle Scholar
• Clemens, P.R., Kochanek, S., Sunada, Y., Chan, S., Chen, H.H., Campbell, K.P., Caskey, C.T. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 1996, 3, 965–972.
   PubMed Web of Science ®Google Scholar
• Dong, J.Y., Fan, P.D., Frizzell, R.A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 1996, 7, 2101–2112.
   PubMed Web of Science ®Google Scholar
• Shenk, T.E., Adenoviridae: the viruses and their replication. In: Fields Virology (p. 2111–2148), David M. Knipe, P.M.H., Diane E. Griffin Malcolm, A. Martin Robert, A.Lamb, , eds. New York: Lippincott Williams & Wilkins, 2006.
   Google Scholar
• Coffin, J.M., Hughes, S.H., Varmus, H.E., Retroviruses. Woodbury, NY: Cold Spring Harbor Laboratory Press, 1997.
   Google Scholar
• Schaffer, D.V., Koerber, J.T., Lim, K.I. Molecular engineering of viral gene delivery vehicles. Annu. Rev. Biomed. Eng. 2008, 10, 169–194.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fischer, A., Cavazzana-Calvo, M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003, 302, 415–419.
   PubMed Web of Science ®Google Scholar
• Lewis, P., Hensel, M., Emerman, M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992, 11, 3053–3058.
   PubMed Web of Science ®Google Scholar
• Weinberg, J.B., Matthews, T.J., Cullen, B.R., Malim, M.H. Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J. Exp. Med. 1991, 174, 1477–1482.
   PubMed Web of Science ®Google Scholar
• Case, S.S., Price, M.A., Jordan, C.T., Yu, X.J., Wang, L., Bauer, G., Haas, D.L., Xu, D., Stripecke, R., Naldini, L., Kohn, D.B., Crooks, G.M. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 2988–2993.
   PubMed Web of Science ®Google Scholar
• Naldini, L., Blömer, U., Gage, F.H., Trono, D., Verma, I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11382–11388.
   PubMed Web of Science ®Google Scholar
• De Palma, M., Montini, E., Santoni de Sio, F.R., Benedicenti, F., Gentile, A., Medico, E., Naldini, L. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood. 2005, 105, 2307–2315.
   PubMed Web of Science ®Google Scholar
• Frecha, C., Szécsi, J., Cosset, F.L., Verhoeyen, E. Strategies for targeting lentiviral vectors. Curr. Gene Ther. 2008, 8, 449–460.
   PubMed Web of Science ®Google Scholar
• Zaiss, A.K., Son, S., Chang, L.J. RNA 3′ read through of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J. Virol. 2002, 76, 7209–7219.
   PubMed Web of Science ®Google Scholar
• Emery, D.W., Yannaki, E., Tubb, J., Nishino, T., Li, Q., Stamatoyannopoulos, G. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood. 2002, 100, 2012–2019.
   PubMed Web of Science ®Google Scholar
• Cronin, J., Zhang, X.Y., Reiser, J. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 2005, 5, 387–398.
   PubMed Web of Science ®Google Scholar
• Carneiro, F.A., Lapido-Loureiro, P.A., Cordo, S.M., Stauffer, F., Weissmüller, G., Bianconi, M.L., Juliano, M.A., Juliano, L., Bisch, P.M., Da Poian, A.T., Poian, A.T. Probing the interaction between vesicular stomatitis virus and phosphatidylserine. Eur. Biophys. J. 2006, 35, 145–154.
   PubMedGoogle Scholar
• Coil, D.A., Miller, A.D. Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J. Virol. 2004, 78, 10920–10926.
   PubMed Web of Science ®Google Scholar
• Coil, D.A., Miller, A.D. Enhancement of enveloped virus entry by phosphatidylserine. J. Virol. 2005, 79, 11496–11500.
   PubMed Web of Science ®Google Scholar
• Watson, D.J., Kobinger, G.P., Passini, M.A., Wilson, J.M., Wolfe, J.H. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther. 2002, 5, 528–537.
   PubMed Web of Science ®Google Scholar
• Ory, D.S., Neugeboren, B.A., Mulligan, R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11400–11406.
   PubMed Web of Science ®Google Scholar
• DePolo, N.J., Reed, J.D., Sheridan, P.L., Townsend, K., Sauter, S.L., Jolly, D.J., Dubensky, T.W.Jr. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. 2000, 2, 218–222.
   PubMed Web of Science ®Google Scholar
• Hanawa, H., Kelly, P.F., Nathwani, A.C., Persons, D.A., Vandergriff, J.A., Hargrove, P., Vanin, E.F., Nienhuis, A.W. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol. Ther. 2002, 5, 242–251.
   PubMed Web of Science ®Google Scholar
• Kelly, P.F., Vandergriff, J., Nathwani, A., Nienhuis, A.W., Vanin, E.F. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood. 2000, 96, 1206–1214.
   PubMedGoogle Scholar
• Porter, C.D., Collins, M.K., Tailor, C.S., Parkar, M.H., Cosset, F.L., Weiss, R.A., Takeuchi, Y. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum. Gene Ther. 1996, 7, 913–919.
   PubMed Web of Science ®Google Scholar
• Sandrin, V., Boson, B., Salmon, P., Gay, W., Nègre, D., Le Grand, R., Trono, D., Cosset, F.L. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood. 2002, 100, 823–832.
   PubMed Web of Science ®Google Scholar
• Jakobsson, J., Lundberg, C. Lentiviral vectors for use in the central nervous system. Mol. Ther. 2006, 13, 484–493.
   PubMed Web of Science ®Google Scholar
• Wong, L.F., Azzouz, M., Walmsley, L.E., Askham, Z., Wilkes, F.J., Mitrophanous, K.A., Kingsman, S.M., Mazarakis, N.D. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 2004, 9, 101–111.
   PubMed Web of Science ®Google Scholar
• Kahl, C.A., Pollok, K., Haneline, L.S., Cornetta, K. Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions. Mol. Ther. 2005, 11, 470–482.
   PubMedGoogle Scholar
• Klimstra, W.B., Nangle, E.M., Smith, M.S., Yurochko, A.D., Ryman, K.D. DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J. Virol. 2003, 77, 12022–12032.
   PubMed Web of Science ®Google Scholar
• Kahl, C.A., Marsh, J., Fyffe, J., Sanders, D.A., Cornetta, K. Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus. J. Virol. 2004, 78, 1421–1430.
   PubMed Web of Science ®Google Scholar
• Kang, Y., Stein, C.S., Heth, J.A., Sinn, P.L., Penisten, A.K., Staber, P.D., Ratliff, K.L., Shen, H., Barker, C.K., Martins, I., Sharkey, C.M., Sanders, D.A., McCray, P.B.Jr, Davidson, B.L. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J. Virol. 2002, 76, 9378–9388.
   PubMed Web of Science ®Google Scholar
• Morizono, K., Bristol, G., Xie, Y.M., Kung, S.K., Chen, I.S. Antibody-directed targeting of retroviral vectors via cell surface antigens. J. Virol. 2001, 75, 8016–8020.
   PubMed Web of Science ®Google Scholar
• Gardner, J.P., Frolov, I., Perri, S., Ji, Y., MacKichan, M.L., zur Megede, J., Chen, M., Belli, B.A., Driver, D.A., Sherrill, S., Greer, C.E., Otten, G.R., Barnett, S.W., Liu, M.A., Dubensky, T.W., Polo, J.M. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 2000, 74, 11849–11857.
   PubMed Web of Science ®Google Scholar
• Yang, L., Yang, H., Rideout, K., Cho, T., Joo, K.I., Ziegler, L., Elliot, A., Walls, A., Yu, D., Baltimore, D., Wang, P. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 2008, 26, 326–334.
   PubMed Web of Science ®Google Scholar
• Lavillette, D., Russell, S.J., Cosset, F.L. Retargeting gene delivery using surface-engineered retroviral vector particles. Curr. Opin. Biotechnol. 2001, 12, 461–466.
   PubMedGoogle Scholar
• Sandrin, V., Russell, S.J., Cosset, F.L. Targeting retroviral and lentiviral vectors. Curr. Top. Microbiol. Immunol. 2003, 281, 137–178.
   PubMed Web of Science ®Google Scholar
• Waehler, R., Russell, S.J., Curiel, D.T. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 2007, 8, 573–587.
   PubMed Web of Science ®Google Scholar
• Gollan, T.J., Green, M.R. Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. J. Virol. 2002, 76, 3558–3563.
   PubMed Web of Science ®Google Scholar
• Han, X., Kasahara, N., Kan, Y.W. Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 9747–9751.
   PubMed Web of Science ®Google Scholar
• Valsesia-Wittmann, S., Drynda, A., Deléage, G., Aumailley, M., Heard, J.M., Danos, O., Verdier, G., Cosset, F.L. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 1994, 68, 4609–4619.
   PubMedGoogle Scholar
• Guibinga, G.H., Hall, F.L., Gordon, E.M., Ruoslahti, E., Friedmann, T. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol. Ther. 2004, 9, 76–84.
   PubMedGoogle Scholar
• Somia, N.V., Zoppé, M., Verma, I.M. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7570–7574.
   PubMedGoogle Scholar
• Benedict, C.A., Tun, R.Y., Rubinstein, D.B., Guillaume, T., Cannon, P.M., Anderson, W.F. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum. Gene Ther. 1999, 10, 545–557.
   PubMed Web of Science ®Google Scholar
• Jiang, A., Chu, T.H., Nocken, F., Cichutek, K., Dornburg, R. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J. Virol. 1998, 72, 10148–10156.
   PubMed Web of Science ®Google Scholar
• Martín, F., Chowdhury, S., Neil, S., Phillipps, N., Collins, M.K. Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol. Ther. 2002, 5, 269–274.
   PubMedGoogle Scholar
• Maurice, M., Verhoeyen, E., Salmon, P., Trono, D., Russell, S.J., Cosset, F.L. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood. 2002, 99, 2342–2350.
   PubMed Web of Science ®Google Scholar
• Chadwick, M.P., Morling, F.J., Cosset, F.L., Russell, S.J. Modification of retroviral tropism by display of IGF-I. J. Mol. Biol. 1999, 285, 485–494.
   PubMedGoogle Scholar
• Nguyen, T.H., Pagès, J.C., Farge, D., Briand, P., Weber, A. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum. Gene Ther. 1998, 9, 2469–2479.
   PubMed Web of Science ®Google Scholar
• Snitkovsky, S., Young, J.A. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 7063–7068.
   PubMedGoogle Scholar
• Boerger, A.L., Snitkovsky, S., Young, J.A. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9867–9872.
   PubMedGoogle Scholar
• Roux, P., Jeanteur, P., Piechaczyk, M. A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9079–9083.
   PubMed Web of Science ®Google Scholar
• Morizono, K., Xie, Y., Ringpis, G.E., Johnson, M., Nassanian, H., Lee, B., Wu, L., Chen, I.S. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 2005, 11, 346–352.
   PubMed Web of Science ®Google Scholar
• Somia, N.V., Miyoshi, H., Schmitt, M.J., Verma, I.M. Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping. J. Virol. 2000, 74, 4420–4424.
   PubMed Web of Science ®Google Scholar
• Endres, M.J., Jaffer, S., Haggarty, B., Turner, J.D., Doranz, B.J., O’Brien, P.J., Kolson, D.L., Hoxie, J.A. Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes. Science. 1997, 278, 1462–1464.
   PubMedGoogle Scholar
• Lamb, R.A. Paramyxovirus fusion: a hypothesis for changes. Virology. 1993, 197, 1–11.
   PubMed Web of Science ®Google Scholar
• Lin, A.H., Kasahara, N., Wu, W., Stripecke, R., Empig, C.L., Anderson, W.F., Cannon, P.M. Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein. Hum. Gene Ther. 2001, 12, 323–332.
   PubMed Web of Science ®Google Scholar
• Yang, L., Bailey, L., Baltimore, D., Wang, P. Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11479–11484.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.L., Bousso, P., Deist, F.L., Fischer, A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000, 288, 669–672.
   PubMed Web of Science ®Google Scholar
• Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M.G., Bordignon, C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002, 296, 2410–2413.
   PubMed Web of Science ®Google Scholar
• Ott, M.G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., Naundorf, S., Brinkmann, A., Deichmann, A., Fischer, M., Ball, C., Pilz, I., Dunbar, C., Du, Y., Jenkins, N.A., Copeland, N.G., Lüthi, U., Hassan, M., Thrasher, A.J., Hoelzer, D., von Kalle, C., Seger, R., Grez, M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006, 12, 401–409.
   PubMed Web of Science ®Google Scholar
• Bushman, F., Lewinski, M., Ciuffi, A., Barr, S., Leipzig, J., Hannenhalli, S., Hoffmann, C. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 2005, 3, 848–858.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo, M., Fischer, A. Gene therapy for severe combined immunodeficiency: are we there yet? J. Clin. Invest. 2007, 117, 1456–1465.
   PubMed Web of Science ®Google Scholar
• Gaspar, H.B., Parsley, K.L., Howe, S., King, D., Gilmour, K.C., Sinclair, J., Brouns, G., Schmidt, M., Von Kalle, C., Barington, T., Jakobsen, M.A., Christensen, H.O., Al Ghonaium, A., White, H.N., Smith, J.L., Levinsky, R.J., Ali, R.R., Kinnon, C., Thrasher, A.J. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004, 364, 2181–2187.
   PubMed Web of Science ®Google Scholar
• Goverdhana, S., Puntel, M., Xiong, W., Zirger, J.M., Barcia, C., Curtin, J.F., Soffer, E.B., Mondkar, S., King, G.D., Hu, J., Sciascia, S.A., Candolfi, M., Greengold, D.S., Lowenstein, P.R., Castro, M.G. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 2005, 12, 189–211.
   PubMed Web of Science ®Google Scholar
• Frecha, C., Szecsi, J., Cosset, F.L., Verhoeyen, E. Strategies for targeting lentiviral vectors. Curr. Gene Ther. 2008, 8, 449–460.
   PubMed Web of Science ®Google Scholar
• Moreau, T., Bardin, F., Imbert, J., Chabannon, C., Tonnelle, C. Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Mol. Ther. 2004, 10, 45–56.
   PubMed Web of Science ®Google Scholar
• Laurie, K.L., Blundell, M.P., Baxendale, H.E., Howe, S.J., Sinclair, J., Qasim, W., Brunsberg, U., Thrasher, A.J., Holmdahl, R., Gustafsson, K. Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector. Gene Ther. 2007, 14, 1623–1631.
   PubMed Web of Science ®Google Scholar
• Taher, T.E., Tulone, C., Fatah, R., D’Acquisto, F., Gould, D.J., Mageed, R.A. Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors. Gene Ther. 2008, 15, 998–1006.
   PubMedGoogle Scholar
• Lutzko, C., Senadheera, D., Skelton, D., Petersen, D., Kohn, D.B. Lentivirus vectors incorporating the immunoglobulin heavy chain enhancer and matrix attachment regions provide position-independent expression in B lymphocytes. J. Virol. 2003, 77, 7341–7351.
   PubMedGoogle Scholar
• Werner, M., Kraunus, J., Baum, C., Brocker, T. B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element. Gene Ther. 2004, 11, 992–1000.
   PubMedGoogle Scholar
• Indraccolo, S., Minuzzo, S., Roccaforte, F., Zamarchi, R., Habeler, W., Stievano, L., Tosello, V., Klein, D., Günzburg, W.H., Basso, G., Chieco-Bianchi, L., Amadori, A. Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood. 2001, 98, 3607–3617.
   PubMedGoogle Scholar
• Marodon, G., Mouly, E., Blair, E.J., Frisen, C., Lemoine, F.M., Klatzmann, D. Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood. 2003, 101, 3416–3423.
   PubMed Web of Science ®Google Scholar
• Dardalhon, V., Herpers, B., Noraz, N., Pflumio, F., Guetard, D., Leveau, C., Dubart-Kupperschmitt, A., Charneau, P., Taylor, N. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther. 2001, 8, 190–198.
   PubMed Web of Science ®Google Scholar
• Lois, C., Hong, E.J., Pease, S., Brown, E.J., Baltimore, D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002, 295, 868–872.
   PubMed Web of Science ®Google Scholar
• Bonkobara, M., Zukas, P.K., Shikano, S., Nakamura, S., Cruz, P.D.Jr, Ariizumi, K. Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter. J. Immunol. 2001, 167, 6893–6900.
   PubMedGoogle Scholar
• Dresch, C., Edelmann, S.L., Marconi, P., Brocker, T. Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J. Immunol. 2008, 181, 4495–4506.
   PubMedGoogle Scholar
• Kozmik, Z., Czerny, T., Busslinger, M. Alternatively spliced insertions in the paired domain restrict the DNA sequence specificity of Pax6 and Pax8. EMBO J. 1997, 16, 6793–6803.
   PubMedGoogle Scholar
• Lopes, L., Dewannieux, M., Gileadi, U., Bailey, R., Ikeda, Y., Whittaker, C., Collin, M.P., Cerundolo, V., Tomihari, M., Ariizumi, K., Collins, M.K. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J. Virol. 2008, 82, 86–95.
   PubMed Web of Science ®Google Scholar
• Morita, Y., Yang, J., Gupta, R., Shimizu, K., Shelden, E.A., Endres, J., Mulé, J.J., McDonagh, K.T., Fox, D.A. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J. Clin. Invest. 2001, 107, 1275–1284.
   PubMed Web of Science ®Google Scholar
• Ageichik, A., Collins, M.K., Dewannieux, M. Lentivector targeting to dendritic cells. Mol. Ther. 2008, 16, 1008–1009.
   PubMedGoogle Scholar
• Cui, Y., Golob, J., Kelleher, E., Ye, Z., Pardoll, D., Cheng, L. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood. 2002, 99, 399–408.
   PubMed Web of Science ®Google Scholar
• Schröder, A.R., Shinn, P., Chen, H., Berry, C., Ecker, J.R., Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002, 110, 521–529.
   PubMed Web of Science ®Google Scholar
• Lesniak, M.S., Kelleher, E., Pardoll, D., Cui, Y. Targeted gene therapy to antigen-presenting cells in the central nervous system using hematopoietic stem cells. Neurol. Res. 2005, 27, 820–826.
   PubMed Web of Science ®Google Scholar
• Follenzi, A., Battaglia, M., Lombardo, A., Annoni, A., Roncarolo, M.G., Naldini, L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood. 2004, 103, 3700–3709.
   PubMed Web of Science ®Google Scholar
• Annoni, A., Battaglia, M., Follenzi, A., Lombardo, A., Sergi-Sergi, L., Naldini, L., Roncarolo, M.G. The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells. Blood. 2007, 110, 1788–1796.
   PubMedGoogle Scholar
• Prioleau, M.N., Nony, P., Simpson, M., Felsenfeld, G. An insulator element and condensed chromatin region separate the chicken beta-globin locus from an independently regulated erythroid-specific folate receptor gene. EMBO J. 1999, 18, 4035–4048.
   PubMedGoogle Scholar
• Zhang, F., Thornhill, S.I., Howe, S.J., Ulaganathan, M., Schambach, A., Sinclair, J., Kinnon, C., Gaspar, H.B., Antoniou, M., Thrasher, A.J. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood. 2007, 110, 1448–1457.
   PubMed Web of Science ®Google Scholar
• Recillas-Targa, F., Valadez-Graham, V., Farrell, C.M. Prospects and implications of using chromatin insulators in gene therapy and transgenesis. Bioessays. 2004, 26, 796–807.
   PubMed Web of Science ®Google Scholar
• Negri, D.R., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Buffa, V., Bona, R., Leone, P., Klotman, M.E., Cara, A. Successful immunization with a single injection of non-integrating lentiviral vector. Mol. Ther. 2007, 15, 1716–1723.
   PubMed Web of Science ®Google Scholar
• Gollan, T.J., Green, M.R. Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. J. Virol. 2002, 76, 3558–3563.
   PubMed Web of Science ®Google Scholar
• Kueng, H.J., Leb, V.M., Haiderer, D., Raposo, G., Thery, C., Derdak, S.V., Schmetterer, K.G., Neunkirchner, A., Sillaber, C., Seed, B., Pickl, W.F. General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J. Virol. 2007, 81, 8666–8676.
   PubMedGoogle Scholar
• Morizono, K., Xie, Y., Ringpis, G.E., Johnson, M., Nassanian, H., Lee, B., Wu, L., Chen, I.S. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 2005, 11, 346–352.
   PubMed Web of Science ®Google Scholar
• Maurice, M., Mazur, S., Bullough, F.J., Salvetti, A., Collins, M.K., Russell, S.J., Cosset, F.L. Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins. Blood. 1999, 94, 401–410.
   PubMedGoogle Scholar
• Fielding, A.K., Maurice, M., Morling, F.J., Cosset, F.L., Russell, S.J. Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood. 1998, 91, 1802–1809.
   PubMedGoogle Scholar
• Gennari, F., Lopes, L., Verhoeyen, E., Marasco, W., Collins, M.K. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum. Gene Ther. 2009, 20, 554–562.
   PubMedGoogle Scholar
• Karavanas, G., Marin, M., Bachrach, E., Papavassiliou, A.G., Piechaczyk, M. The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells. Virus Res. 2002, 83, 57–69.
   PubMed Web of Science ®Google Scholar
• Marin, M., Noël, D., Valsesia-Wittman, S., Brockly, F., Etienne-Julan, M., Russell, S., Cosset, F.L., Piechaczyk, M. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J. Virol. 1996, 70, 2957–2962.
   PubMed Web of Science ®Google Scholar
• Chowdhury, S., Chester, K.A., Bridgewater, J., Collins, M.K., Martin, F. Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors. Mol. Ther. 2004, 9, 85–92.
   PubMed Web of Science ®Google Scholar
• Dreja, H., Piechaczyk, M. The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol. J. 2006, 3, 69.
   PubMedGoogle Scholar
• Verhoeyen, E., Dardalhon, V., Ducrey-Rundquist, O., Trono, D., Taylor, N., Cosset, F.L. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood. 2003, 101, 2167–2174.
   PubMed Web of Science ®Google Scholar
• Verhoeyen, E., Wiznerowicz, M., Olivier, D., Izac, B., Trono, D., Dubart-Kupperschmitt, A., Cosset, F.L. Novel lentiviral vectors displaying “early-acting cytokines” selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood. 2005, 106, 3386–3395.
   PubMedGoogle Scholar
• Pan, D., Gunther, R., Duan, W., Wendell, S., Kaemmerer, W., Kafri, T., Verma, I.M., Whitley, C.B. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol. Ther. 2002, 6, 19–29.
   PubMed Web of Science ®Google Scholar
• Kueng, H.J., Leb, V.M., Haiderer, D., Raposo, G., Thery, C., Derdak, S.V., Schmetterer, K.G., Neunkirchner, A., Sillaber, C., Seed, B., Pickl, W.F. General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J. Virol. 2007, 81, 8666–8676.
   PubMedGoogle Scholar
• Chandrashekran, A., Gordon, M.Y., Casimir, C. Targeted retroviral transduction of c-kit+ hematopoietic cells using novel ligand display technology. Blood. 2004, 104, 2697–2703.
   PubMedGoogle Scholar
• Kaikkonen, M.U., Lesch, H.P., Pikkarainen, J., Räty, J.K., Vuorio, T., Huhtala, T., Taavitsainen, M., Laitinen, T., Tuunanen, P., Gröhn, O., Närvänen, A., Airenne, K.J., Ylä-Herttuala, S. (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery. Gene Ther. 2009, 16, 894–904.
   PubMed Web of Science ®Google Scholar
• Liang, M., Pariente, N., Morizono, K., Chen, I.S. Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells. J. Gene Med. 2009, 11, 185–196.
   PubMedGoogle Scholar
• Yang, H., Ziegler, L., Joo, K.I., Cho, T., Lei, Y., Wang, P. Gamma-retroviral vectors enveloped with an antibody and an engineered fusogenic protein achieved antigen-specific targeting. Biotechnol. Bioeng. 2008, 101, 357–368.
   PubMedGoogle Scholar
• Lei, Y., Joo, K.I., Wang, P. Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors. J. Biol. Eng. 2009, 3, 8.
   PubMedGoogle Scholar
• Ziegler, L., Yang, L., Joo, K., Yang, H., Baltimore, D., Wang, P. Targeting lentiviral vectors to antigen-specific immunoglobulins. Hum. Gene Ther. 2008, 19, 861–872.
   PubMedGoogle Scholar
• Yang, H., Joo, K.I., Ziegler, L., Wang, P. Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm. Res. 2009, 26, 1432–1445.
   PubMedGoogle Scholar
• Froelich, S., Ziegler, L., Stroup, K., Wang, P. Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule. Biotechnol. Bioeng. 2009, 104, 206–215.
   PubMedGoogle Scholar
• Funke, S., Maisner, A., Mühlebach, M.D., Koehl, U., Grez, M., Cattaneo, R., Cichutek, K., Buchholz, C.J. Targeted cell entry of lentiviral vectors. Mol. Ther. 2008, 16, 1427–1436.
   PubMed Web of Science ®Google Scholar
• Logan, A.C., Lutzko, C., Kohn, D.B. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr. Opin. Biotechnol. 2002, 13, 429–436.
   PubMed Web of Science ®Google Scholar
• Pawliuk, R., Westerman, K.A., Fabry, M.E., Payen, E., Tighe, R., Bouhassira, E.E., Acharya, S.A., Ellis, J., London, I.M., Eaves, C.J., Humphries, R.K., Beuzard, Y., Nagel, R.L., Leboulch, P. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001, 294, 2368–2371.
   PubMed Web of Science ®Google Scholar
• Lavenu-Bombled, C., Izac, B., Legrand, F., Cambot, M., Vigier, A., Massé, J.M., Dubart-Kupperschmitt, A. Glycoprotein Ibalpha promoter drives megakaryocytic lineage-restricted expression after hematopoietic stem cell transduction using a self-inactivating lentiviral vector. Stem. Cells 2007, 25, 1571–1577.
   PubMedGoogle Scholar